Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
about
Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist.Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis.Further progress for therapeutic solutions in psoriasis.Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
P2860
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Comparison of ixekizumab with ...... om IXORA-S, a phase III study.
@en
type
label
Comparison of ixekizumab with ...... om IXORA-S, a phase III study.
@en
prefLabel
Comparison of ixekizumab with ...... om IXORA-S, a phase III study.
@en
P2093
P2860
P50
P356
P1476
Comparison of ixekizumab with ...... rom IXORA-S, a phase III study
@en
P2093
C Ferrandiz
C Henneges
IXORA-S investigators
J P Lacour
P2860
P304
P356
10.1111/BJD.15666
P407
P577
2017-07-19T00:00:00Z